Crizotinib
- PDF / 169,347 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 72 Downloads / 177 Views
1
S
Various toxicities: 5 case report In a retrospective analysis of 113 patients, 5 patients [ages and sexes not stated] were described, who developed skin rash (1 patient), onycholysis (1 patient), renal toxicity (1 patient), cardiac toxicity (1 patient) or liver toxicity (1 patient) during treatment with crizotinib for lung adenocarcinoma [route, dosage, duration of treatment to reactions onsets not stated; not all outcomes stated]. The patient, who developed cardiac toxicity, died [immediate cause of death not stated]. Crizotinib therapy was changed to ceritinib in the patient with liver toxicity. Author comment: "10 patients showed crizotinib-induced toxicity (1 presented skin rash, 1 presented [onycholysis]. . .1 had renal toxicity and 1 presented cardiac toxicity and died). . .and 1 patient had his treatment shifted to ceritinib (because of liver toxicity)." Correia JB, et al. P2.11 Three Years of Experience with ALK-Positive Patients. Journal of Thoracic Oncology 14 (Suppl. 2): S1189 abstr. P2.11, No. 11, Nov 2019. Available from: URL: https://doi.org/10.1016/j.jtho.2019.09.174 [abstract] 803435284 Portugal
0114-9954/19/1780-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 23 Nov 2019 No. 1780
Data Loading...
